PD-1/PD-L1-IN-23

PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1].

Product Specifications

CAS Number

[2597056-04-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pd-1-pd-l1-in-23.html

Concentration

10mM

Purity

99.98

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

ClC1=CC(CN[C@@H](C(OCC)=O)CO)=C(OCC2=CC3=NON=C3C=C2)C=C1OCC4=C(Br)C(C5=CC=CC=C5)=CC=C4.[H]Cl

Molecular Formula

C32H30BrCl2N3O6

Molecular Weight

703.41

Precautions

H302, H315, H319

References & Citations

[1]Liu L, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021;64 (12) :8391-8409.